Enhabit, Inc. (NYSE:EHAB) Given Average Rating of “Hold” by Analysts

Shares of Enhabit, Inc. (NYSE:EHAB) have been given a consensus recommendation of “Hold” by the six brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $8.75.

Several equities analysts recently commented on EHAB shares. Leerink Partners restated a “market perform” rating and set a $8.00 target price (down previously from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. Jefferies Financial Group raised Enhabit from a “hold” rating to a “buy” rating and lifted their price objective for the company from $8.25 to $9.50 in a report on Monday, December 9th.

Insider Buying and Selling

In related news, Director Jeffrey Bolton bought 4,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $8.69 per share, with a total value of $34,760.00. Following the completion of the purchase, the director now owns 98,144 shares in the company, valued at approximately $852,871.36. The trade was a 4.25 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Stuart M. Mcguigan bought 15,000 shares of Enhabit stock in a transaction dated Tuesday, December 10th. The shares were bought at an average price of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the transaction, the director now directly owns 46,810 shares of the company’s stock, valued at $412,396.10. This represents a 47.15 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. raised its position in shares of Enhabit by 19.6% during the third quarter. Franklin Resources Inc. now owns 32,382 shares of the company’s stock worth $256,000 after acquiring an additional 5,317 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Enhabit by 37.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 305,245 shares of the company’s stock worth $2,411,000 after purchasing an additional 83,707 shares during the last quarter. Paradice Investment Management LLC lifted its position in Enhabit by 12.8% during the 4th quarter. Paradice Investment Management LLC now owns 1,780,113 shares of the company’s stock valued at $13,903,000 after purchasing an additional 201,997 shares during the period. Systematic Financial Management LP boosted its stake in shares of Enhabit by 12.2% in the 3rd quarter. Systematic Financial Management LP now owns 1,838,199 shares of the company’s stock valued at $14,522,000 after purchasing an additional 199,235 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Enhabit during the 3rd quarter worth approximately $215,000.

Enhabit Price Performance

Shares of EHAB opened at $8.26 on Thursday. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85. The company has a 50-day moving average price of $8.10 and a two-hundred day moving average price of $7.90. The stock has a market cap of $415.35 million, a price-to-earnings ratio of -3.56 and a beta of 1.83. Enhabit has a 12 month low of $6.85 and a 12 month high of $11.74.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.